🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial
2026-526122-41-00Colorectal cancer with peritoneal metastases
Uppsala University Hospital
Not possible to specify
Sweden
15/07/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
2025-522734-31-00Acute Ischemic Stroke
Takeda Development Center Americas Inc.
Nervous System Diseases
Greece, Belgium, France, Germany
14/07/2026
Phase II
A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT
2025-523633-25-00cutaneous squamous cell carcinoma
Fondazione GONO Plus
Neoplasms
Italy
14/07/2026
Phase II
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease
2025-524139-38-00Antibody-mediated Kidney Disease
AstraZeneca AB
Immune System Diseases
France, Germany, Italy, Belgium, Poland, Spain
13/07/2026
Phase II
Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)
2025-525096-83-00Relapsed/refractory Multiple myeloma
Polish Myeloma Consortium
Hemic and Lymphatic Diseases
Poland
13/07/2026
Phase II
Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)
2025-523725-17-00HIV-1 disease
Region Midtjylland
Immune System Diseases
Sweden, Norway, Denmark, Iceland
13/07/2026
Phase II
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)
2026-525282-50-00Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc.
Neoplasms
Netherlands, Germany, Spain
13/07/2026
Phase II
SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study
2025-523293-17-00Cluster headache
Leids Universitair Medisch Centrum (LUMC)
Nervous System Diseases
Netherlands
13/07/2026
Phase II
Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)
2025-524442-10-00Long-term persistence of SARS-CoV-2
Goethe University Frankfurt
Virus Diseases
Germany, Spain
13/07/2026
Phase II
Prospective trial of [18F]AlF-FAPI-74 for PET imaging of fibroblast activation protein in patients with endometriosis
2026-525272-25-00endometriosis
UZ Leuven
Female Urogenital Diseases and Pregnancy Complications
Belgium
10/07/2026
Phase II
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…
Elevar Therapeutics Inc.
Neoplasms
France, Spain
09/07/2026
Phase II
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
2026-526036-38-00Pleural mesothelioma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
09/07/2026
Phase II
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland
08/07/2026
Phase II
Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)
2026-525260-18-00Multiple Sclerosis
Amsterdam UMC Stichting
Nervous System Diseases
Netherlands
08/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
2025-523503-30-00Narcolepsy
Eisai Limited
Nervous System Diseases
Belgium, Italy, Spain, Germany
08/07/2026
Phase II
HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
2025-524967-19-00Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Netherlands, Sweden, Germany
08/07/2026
Phase II
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Belgium, Ireland, Germany, Norway, Italy, France, Spain
07/07/2026
Phase II
Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID
2025-524374-42-00allogeneic haematopoietic stem cell transplant recipient, l…
Hospices Civils De Lyon
Surgical Procedures, Operative
France
06/07/2026
Phase II
Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)
2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…
Assistance Publique Hopitaux De Paris
Therapeutics
France
06/07/2026
Phase II
Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I
2024-510793-24-00suspected malignant pulmonary disease (lung lesions and/or …
Universitair Medisch Centrum Groningen
Neoplasms
Netherlands
06/07/2026
Phase II
iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy
2025-521506-17-01Hypoxic-ischemic brain injury (HIBI) because of Perinatal A…
Universitair Medisch Centrum Utrecht
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands
06/07/2026
Phase II
The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)
2025-522961-31-01Depression
Kobenhavns Universitet, Koebenhavns Universitet
Mental Disorders
Denmark
03/07/2026
Phase II
Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients
2025-522453-20-00Acute lymphoblastic leukemia and lymphoma
Oslo University Hospital HF
Neoplasms
Norway
03/07/2026
Phase II
A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder
2024-520319-42-01Major Depressive Disorder
Ostfold Hospital Trust
Psychological Phenomena
Norway
03/07/2026
Phase II
A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024
2024-517799-40-00Advanced squamous non-small cell lung cancer
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
Neoplasms
Italy
03/07/2026
Rows per page Showing 126–150 of 726
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.